India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report

Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3kq04eV
via IFTTT